DE102004017739A1 - New 2-amino-imidazo(4,5-d)pyridazin-4-one derivatives are dipeptidyl-peptidase IV inhibitors useful in the treatment of e.g. diabetes mellitus, autoimmune disease, rheumatoid arthritis, and multiple sclerosis - Google Patents

Abstract

2-Amino-imidazo[4,5-d]pyridazin-4-one derivatives or their tautomers, enantiomers, and/or diastereomers, prodrugs or salts are new. 2-Amino-imidazo[4,5-d]pyridazin-4-one derivatives of formula (I) and their tautomers, enantiomers, and/or diastereomers, prodrugs and salts are new. R1(hetero)arylmethyl or (hetero)arylethyl, (hetero)arylcarbonylmethyl or (hetero)arylprop-2-enyl, where the propenyl chain is optionally substituted; X : N or C-R5; R5H or 1-3C alkyl; R2H, 1-6C alkyl (optionally substituted), or (hetero)aryl (all optionally substituted)); Ra3-7C cycloalkyl, where 1 or 2 methylene groups may be replaced O, S, -NH- or -N(1-3C alkyl) group, or by a carbonyl, sulfinyl or sulfonyl; or CF3, (hetero)aryl, CN, carboxy, 1-3C alkoxy-carbonyl, aminocarbonyl, 1-3C alkylamino-carbonyl, di-(1-3C alkyl)-aminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-(1-3C alkyl)-piperazin-1-ylcarbonyl, (hetero)arylcarbonyl, 1-3C alkylsulfinyl, 1-3C alkylsulfonyl, OH, 1-3C alkoxy, 1-3C alkylsulfanyl, amino, 1-3C alkylamino, di-(1-3C alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl or 4-(1-3C alkyl)-piperazin-1-yl; a CF3, carboxy, 1-4C alkoxy-carbonyl, aminocarbonyl, 1-3C alkylamino-carbonyl, di-(1-3C alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-(1-3C alkyl)-piperazin-1-ylcarbonyl, (hetero)arylcarbonyl, 1-3C alkylsulfinyl, 1-3C alkylsulfonyl, 1-4C alkoxy, 1-4C alkylsulfanyl, amino, 1-3C alkylamino or di-(1-3C alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl or 4-(1-3C alkyl)-piperazin-1-yl; 3-7C cycloalkyl, where one or two methylene groups may be replaced by O or S, by -NH- or N(1-3C alkyl), or by a carbonyl, sulfinyl or sulfonyl group; or 3-6C alkenyl or 3-6C alkynyl (all optionally substituted)); R35-7C cycloalkenyl-methyl optionally substituted by a 1-3C alkyl group; (hetero)arylmethyl; a straight or branched 2-8C alkenyl optionally substituted by 1 - 15 F or CN, NO2 or 1-3C alkoxy-carbonyl group; or a straight or branched 3-8C alkynyl optionally substituted by 1 - 9 F or CN, NO2 or 1-3C alkoxy-carbonyl group (all optionally substituted)); R4amino (substituted by R15 and R16 or R15 and R18 or R15 and R20 or R15 and R21); R15H, 1-6C alkyl, 3-6C cycloalkyl, 3-6C cycloalkyl-1-3C alkyl, aryl or aryl-1-3C alkyl ; R16R17-2-3C alkyl, where the 2-3C alkyl moiety is straight-chain and is optionally mono- - tetra-substituted by 1-3C alkyl; R17 and R19amino or 1-3C alkylamino; R183-10C cycloalkyl-1-2C alkyl substituted in the 1 position of the cycloalkyl group by R19 or a 3-10C cycloalkyl substituted in 1 or 2 position by a R19-1-2C alkyl (all optionally substituted); R204C- or 8-10C cycloalkyl, where a methylene group from position 3 onwards of the 4C- or 8-10C cycloalkyl group is replaced by an -NH- (all optionally substituted); and R213-4C- or 8-10C cycloalkyl substituted in the 2 or 3 position by an amino or 1-3C alkylamino (all optionally substituted). Full definitions are given in the "Definitions" section. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Antidiabetic; Ophthalmological; Neuroprotective; Nephrotropic; Antiarthritic; Antiarteriosclerotic; Anorectic; Osteopathic; Sedative; Tranquilizer; Antihypertensive; Antiinflammatory; Gastrointestinal-Gen.; Antiulcer; Antiinfertility; Contraceptive; Immunosuppressive; Antirheumatic; Antithyroid; Uropathic; Virucide; Anti-HIV; Nootropic; Cytostatic; Cerebroprotective; Vasotropic; Antiparkinsonian; Antimigraine; Keratolytic; Antipsoriatic; Antidepressant; Antilipemic; Neuroleptic. MECHANISM OF ACTION : Dipeptidylpeptidase IV (DPP-IV) enzyme inhibitor. 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butyn-1-yl)-5-[(4-methyl-quinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one (a) was tested for DPP-IV inhibitory activity using extract of human colon carcinoma cell line Caco-2 as DPP-IV source. A substrate solution (amido-4-trifluoromethylcoumarin (AFC)) (50 mu l) was placed in microtiter plate. An assay buffer (50 mM Tris HCl, pH 7.8, 50 mM NaCl, 1% dimethyl sulfoxide) was pipetted in the plate. The reaction was started by addition of solubilized Caco-2 protein (30 mu l). (a) Was added to the assay buffer and the reaction was carried out at ambient temperature. The mixture was incubated for 60 minutes and then the fluorescence was determined. (a) Showed DPP-IV inhibition at an IC50 of 1 nM.

Description

deren Tautomere, deren Enantiomere, deren Diastereomere, deren Gemische und deren Salze, insbesonders deren physiologisch verträglichen Salze mit anorganischen oder organischen Säuren, welche wertvolle pharmakologische Eigenschaften aufweisen, insbesondere eine Hemmwirkung auf die Aktivität des Enzyms Dipeptidylpeptidase-IV (DPP-IV), deren Herstellung, deren Verwendung zur Prävention oder Behandlung von Krankheiten oder Zuständen, die in Zusammenhang mit einer erhöhten DPP-IV Aktivität stehen oder die durch Reduktion der DPP-IV Aktivität verhindert oder gemildert werden können, insbesondere von Diabetes mellitus Typ I oder Typ II, die eine Verbindung der allgemeinen Formel (I) oder ein physiologisch verträgliches Salz davon enthaltenden Arzneimittel sowie Verfahren zu deren Herstellung.The present invention relates to novel substituted imidazo [4,5-d] pyridazin-4-ones of the general formula

their tautomers, their enantiomers, their diastereomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids, which have valuable pharmacological properties, in particular an inhibitory effect on the activity of the enzyme dipeptidyl peptidase-IV (DPP-IV), the Manufacture, their use for the prevention or treatment of diseases or conditions associated with increased DPP-IV activity or which can be prevented or alleviated by reduction of DPP-IV activity, in particular diabetes mellitus type I or type II, the a compound of the general formula (I) or a physiologically acceptable salt thereof containing medicament and process for their preparation.

Out WO 03/104229 discloses imidazo [4,5-d] pyridazin-4-ones which in position 2 are substituted by cyclic groups.

In the above formula I mean
R ^{1 is} an arylmethyl or arylethyl group,
a heteroarylmethyl or heteroarylethyl group,
an arylcarbonylmethyl group,
a heteroarylcarbonylmethyl group or
an arylprop-2-enyl or heteroarylprop-2-enyl group in which the propenyl chain may be substituted by 1 to 4 fluorine atoms or a cyano, C _1-3 alkyloxy-carbonyl or nitro group,
R ^{2 is} a hydrogen atom,
a C _1-6 alkyl group,
an aryl or heteroaryl group,
a substituted by a group R _a C _1-6 alkyl group, wherein
R _{a is} a C _3-7 -cycloalkyl group in which one or two methylene groups are each independently represented by an oxygen or sulfur atom, by an -NH- or -N (C _1-3 -alkyl) group or by a carbonyl group, Sulfinyl or sulfonyl group may be replaced,
or a trifluoromethyl, aryl, heteroaryl, cyano, carboxy, C _1-3 -alkoxycarbonyl, aminocarbonyl, C _1-3 -alkylamino-carbonyl, di- (C _1-3 -alkyl) -amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4- (C _1-3 alkyl) piperazin-1-ylcarbonyl -, arylcarbonyl, heteroarylcarbonyl, C _1-3 alkylsulfinyl, C _1-3 alkylsulfonyl, hydroxy, C _1-3 alkoxy, C _1-3 alkylsulfanyl, amino, C _1-3 Alkylamino, di (C _1-3 alkyl) amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl or 4- (C _1-3 alkyl) -piperazin-1-yl group,
a trifluoromethyl, carboxy, C _1-4 alkoxy-carbonyl, aminocarbonyl, C _1-3 -alkylamino-carbonyl, di (C _1-3 -alkyl) -amino-carbonyl, pyrrolidin-1 ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4- (C _1-3 alkyl) piperazin-1-ylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C _{1 3-} alkylsulfinyl, C _1-3 -alkylsulfonyl, C _1-4 alkoxy, C _1-4 alkylsulfanyl, amino, C _1-3 -alkylamino or di (C _1-3 -alkyl) - amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl or 4- (C _1-3 -alkyl) -piperazin-1-yl group,
a C _3-7 cycloalkyl group in which one or two methylene groups are independently represented by an oxygen or sulfur atom, by an -NH- or -N (C _1-3 alkyl) group, or by a carbonyl, sulfinyl or sulfonyl group may be replaced, or
a C _3-6 alkenyl or C _3-6 alkynyl group,
R ^{3 is} a C _5-7 -cycloalkenylmethyl group optionally substituted by a C _1-3 -alkyl group,
an arylmethyl or heteroarylmethyl group,
a straight-chain or branched C _2-6 -alkenyl group which may be substituted by 1 to 15 fluorine atoms or a cyano, nitro or C _1-3 -alkoxycarbonyl group,
or a straight-chain or branched C _3-8 -alkynyl group which may be substituted by 1 to 9 fluorine atoms or a cyano, nitro or C _1-3 -alkoxycarbonyl group,
and
R ^{4 is} an amino group substituted by the radicals R ¹⁵ and R ¹⁶ , in which
R ^{15 is} a hydrogen atom, a C _1-6 alkyl, C _3-6 cycloalkyl, C _3-6 cycloalkyl C _1-3 alkyl, aryl or aryl C _1-3 alkyl group and
R ^{16 represents} an R ¹⁷ -C _2-3 alkyl group, wherein the C _2-3 alkyl portion is straight chain and may be substituted by 1 to 4 C _1-3 alkyl groups, which may be the same or different, and wherein the C _2-3 alkyl group may be linked from position 2 with R ¹⁷ , and
R ^{17 represents} an amino or C _1-3 -alkylamino group,
a substituted by the radicals R ¹⁵ and R ¹⁸ amino group, in the
R ^{15 is} as defined above and R ^{18 is} a C _3-10 -cycloalkyl-C _1-2 -alkyl group which is substituted by R ¹⁹ in the 1-position of the cycloalkyl radical or by an R ¹⁹ in the 1- or 2-position. C _1-2 -alkyl group represents substituted C _3-10 -cycloalkyl group, wherein R ^{19 represents} an amino or C _1-3 -alkylamino group,
a substituted by the radicals R ¹⁵ and R ²⁰ amino group, in the
R ^{15 is} as defined above and R ^{20 is} a C _4-10 -cycloalkyl group in which a methylene group from position 3 of the C _4-10 -cycloalkyl group is replaced by an -NH- group,
or an amino group substituted by the radicals R ¹⁵ and R ²¹ in which
R ^{15 is} as defined above and R ^{21 is} a C _3-10 cycloalkyl group substituted in the 2- or 3-position by an amino or C _1-3 alkylamino group,
where the abovementioned radicals R ¹⁸ , R ²⁰ and R ²¹ can be mono- or disubstituted by R _b , where the substituents can be identical or different and R _{b is} a fluorine atom, a C _1-3 -alkyl, trifluoromethyl, cyano , Amino, C _1-3 -alkylamino, hydroxy or C _1-3 -alkyloxy group, and in which one or two methylene groups of the cycloalkyl radical are each independently represented by an oxygen or sulfur atom or by an -NH- or N (C _1-3 alkyl) - group, or may be replaced by a carbonyl, sulfinyl or sulfonyl group,
where the aryl groups mentioned in the definition of the abovementioned radicals are phenyl or naphthyl groups which can be mono-, di- or trisubstituted independently of one another by R _h , where the substituents can be identical or different and R _{h is} a fluoro , Chloro, bromo or iodo, trifluoromethyl, cyano, nitro, amino, aminocarbonyl, C _1-3 alkoxycarbonyl, aminosulfonyl, methylsulfonyl, acetylamino, methylsulfonylamino, C _1-3 alkyl Represents -, cyclopropyl, ethenyl, ethynyl, morpholinyl, hydroxy, C _1-3 alkyloxy, difluoromethoxy or trifluoromethoxy, and in which additionally each hydrogen atom may be replaced by a fluorine atom,
among the heteroaryl groups mentioned in the definition of the abovementioned radicals, a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, phenanthridinyl, quinolinyl or isoquinolinyl group is to be understood,
or a pyrrolyl, furanyl, thienyl or pyridyl group in which one or two methine groups are replaced by nitrogen atoms,
or an indolyl, benzofuranyl, benzothiophenyl, phenanthridinyl, quinolinyl or isoquinolinyl group in which one to three methine groups are replaced by nitrogen atoms,
or a 1,2-dihydro-2-oxopyridinyl, 1,4-dihydro-4-oxopyridinyl, 2,3-dihydro-3-oxopyridazinyl, 1,2,3,6-tetrahydro -3,6-dioxo-pyridazinyl, 1,2-dihydro-2-oxo-pyrimidinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1,2,3,4-tetrahydro-2,4- dioxo-pyrimidinyl, 1,2-dihydro-2-oxo-pyrazinyl, 1,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl, 2,3-dihydro-2-oxo-indolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxo-1H-benzimidazolyl, 2,3-dihydro-2-oxo-benzoxazolyl, 1,2-dihydro-2-oxo-quinolinyl, 1, 4-dihydro-4-oxo-quinolinyl, 1,2-dihydro-1-oxo-isoquinolinyl, 1,4-dihydro-4-oxo-cinnolinyl, 1,2-dihydro-2-oxo-quinazolinyl, 3,4-dihydro-4-oxo-quinazolinyl, 1,2,3,4-tetrahydro-2,4-dioxo-quinazolinyl, 1,2-dihydro-2-oxoquinoxalinyl, 1,2,3,4 tetrahydro-2,3-dioxo-quinoxalinyl; 1,2-Dihydro-1-oxo-phthalazinyl, 1,2,3,4-tetrahydro-1,4-dioxo-phthalazinyl, chromanyl, coumarinyl, 2,3-dihydro-benzo [1,4] dioxinyl or 3,4-dihydro-3-oxo-2H-benzo [1,4] oxazinyl group,
and the above-mentioned heteroaryl groups may be mono- or disubstituted by R _h , where the substituents may be the same or different and R _{h is} as defined above,
among the in the definition of the above-mentioned cycloalkyl radicals both monocyclic and polycyclic ring systems are to be understood, wherein the multiple cycles can be fused, spiro-linked or bridged, for example, among multiple cycles decalin, octahydroindene, norbornane, spiro [4.4] nonane, spiro [4.5] decane, bicyclo [2.1.1] hexane, bicyclo [2.2.2] octane, bicyclo [3.2.1] octane, bicyclo [3.2.2] nonane, bicyclo [3.3.1] nonane, bicyclo [3.3.2 ] to understand dean or adamantane,
Unless otherwise mentioned, the abovementioned alkyl, alkenyl and alkynyl groups ge can be radically branched or branched,
their tautomers, enantiomers, diastereomers, their mixtures, their prodrugs and their salts.

The carboxy groups mentioned in the definition of the abovementioned radicals may be replaced by a group convertible in vivo into a carboxy group or by a group negatively charged under physiological conditions,
Furthermore, the amino and imino groups mentioned in the definition of the abovementioned radicals may be substituted by an in vivo cleavable radical. Such groups are described, for example, in WO 98/46576 and NM Nielsen et al. in International Journal of Pharmaceutics 39, 75-85 (1987).

Under a convertible in vivo into a carboxy group is, for example, a hydroxymethyl group, an esterified carboxy group with an alcohol in which the alcoholic moiety is preferably a C _1-6 -alkanol, a phenyl-C _1-3 -alkanol, a C _{3- 9} -Cycloalkanol, wherein a C _5-8 cycloalkanol may additionally be substituted by one or two C _1-3 alkyl groups, a C _5-8 cycloalkanol in which a methylene group in the 3- or 4-position by an oxygen atom or is replaced by an optionally substituted by a C _1-3 alkyl, phenyl-C _1-3 alkyl, phenyl-C _1-3 alkoxycarbonyl or C _2-6 alkanoyl substituted imino group and the cycloalkanol part additionally by a or two C _1-3 alkyl groups may be substituted, a C _4-7 cycloalkenol, a C _3-5 alkenol, a phenyl C _3-5 alkenol, a C _3-5 alkinol or phenyl C _{3- 5} -alkynol with the proviso that no bond to the oxygen atom emanates from a carbon atom which is a double or triple Bi a C _3-8 -cycloalkyl-C _1-3 -alkanol, a bicycloalkanol having a total of 8 to 10 carbon atoms, which in the bicycloalkyl moiety may additionally be substituted by one or two C _1-3 -alkyl groups, a 1,3- Dihydro-3-oxo-1-sobenzfuranol or an alcohol of the formula R _p -CO-O- (R _q CR _r) -OH, by doing
R _{p is} a C _1-8 -alkyl, C _5-7 -cycloalkyl, C _1-8 -alkyloxy, C _5-7 -cycloalkyloxy, phenyl or phenyl-C _1-3 -alkyl group,
R _{q is} a hydrogen atom, a C _1-3 alkyl, C _5-7 cycloalkyl or phenyl group and
R _{r represents} a hydrogen atom or a C _1-3 alkyl group,
under a group negatively charged under physiological conditions such as tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl, C _1-6 alkylsulfonylamino, phenylsulfonylamino, benzylsulfonylamino, trifluoromethylsulfonylamino, C _1-6 alkylsulfonylaminocarbonyl, phenylsulfonylamino carbonyl , Benzylsulfonylaminocarbonyl or perfluoroC _1-6 -alkylsulfonylaminocarbonyl group
and under a residue cleavable in vivo from an imino or amino group, for example, a hydroxy group, an acyl group such as an optionally fluorine, chlorine, bromine or iodine atoms, C _1-3 alkyl or C _1-3 alkoxy groups mono- or disubstituted phenylcarbonyl group wherein the substituents may be the same or different, a pyridinoyl group or a C _1-16 alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3 Trichloropropionyl or allyloxycarbonyl group, a C _1-16 -alkoxycarbonyl or C _1-16 -alkylcarbonyloxy group in which hydrogen atoms may be wholly or partly replaced by fluorine or chlorine atoms, such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl , Butoxycarbonyl, tert-butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbon yloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert-butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or Hexadecylcarbonyloxy group, a phenylC _1-6 alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group in which the amino group is mono- or by C _1-6 alkyl or C _3-7 cycloalkyl groups a C _1-3 alkylsulfonyl-C _2-4 alkoxycarbonyl, C _1-3 alkoxy C _2-4 alkoxy C _2-4 alkoxycarbonyl, R _p - CO-O- (R _q CR _r) -O-CO-, C _1-6 alkyl-CO-NN (R _s CR _t) -O-CO- or _{C1-6alkyl-CO-O-} (R _s CR _t ) - (R _s CR _t ) -O-CO group in which R _p to R _r are defined as mentioned above,
R _s and R _t , which may be the same or different, represent hydrogen atoms or C _1-3 alkyl groups,
to understand.

Of Close further the saturated ones mentioned in the preceding and following definitions Alkyl and alkoxy moieties containing more than 2 carbon atoms unless otherwise mentioned was also their branched isomers such as the isopropyl, tert-butyl, isobutyl, etc.

For example, R ¹ has the meaning of a 2-cyanobenzyl, 3-fluorobenzyl, 3-methoxybenzyl, 4-bromo-2-cyanobenzyl, 3-chloro-2-cyanobenzyl, 2-cyano-4-fluorobenzyl, 3,5-dimethoxybenzyl, 2,6-dicyanobenzyl, 5-cyanofuranylmethyl, oxazolylmethyl, isoxazolylmethyl, 5 Methoxycarbonylthienylmethyl, pyridinylmethyl, 3-cyanopyridin-2-ylmethyl, 6-cyanopyridin-2-ylmethyl, 6-fluoropyridin-2-ylmethyl, 3- (2-cyanophenyl) prop-2-enyl, 3 (Pyridin-2-yl) -prop-2-enyl, 3- (pentafluorophenyl) -prop-2-enyl, phenylcarbonylmethyl, 3-methoxyphenylcarbonylmethyl, naphthyl-1-methyl, 4-cyano-naphth-1 ylmethyl, quinolin-1-ylmethyl, 4-cyanoquinolin-1-ylmethyl, isoquinolin-1-ylmethyl, 4-cyanoisoquinolin-1-ylmethyl, 3-methylisoquinolin-1-ylmethyl, quinazolin-2-ylmethyl , 4-methylquinazolin-2-ylmethyl, [1,5] naphthiridin-2-ylmethyl, [1,5] naphthiridin-3-ylmethyl, phenanthridin-6-ylmethyl, quinoxalin-6-ylmethyl or 2, 3-dimethyl-quinoxalin-6-ylmethylgruppe into consideration.

For example, R ² is hydrogen, methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, 2-methylpropyl, tert-butyl, cyclopropyl, cyclobutyl, Cyclopentyl, cyclohexyl, 2-propen-1-yl, 2-propyn-1-yl, cyclopropylmethyl, phenyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-hydroxyethyl, 2- Methoxyethyl, 2-ethoxyethyl, 2- (dimethylamino) ethyl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-1-yl, piperazin-1-yl, carboxy, methoxycarbonyl, Ethoxycarbonyl, carboxymethyl, (methoxycarbonyl) methyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, pyrrolidinocarbonyl, piperidinocarbonyl, morpholinocarbonyl, (aminocarbonyl) methyl, (methylaminocarbonyl) methyl, (dimethylaminocarbonyl) methyl, (pyrrolidinocarbonyl) methyl, (piperidinocarbonyl) methyl, (morpholinocarbonyl) methyl, cyanomethyl, 2-cyanoethyl or pyridinyl.

For example, R ³ has the meaning of a 2-propen-1-yl, 2-methyl-2-propen-1-yl, 1-buten-1-yl, 2-buten-1-yl, 3 Buten-1-yl, 2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl, 2,3-dimethyl-2-buten-1-yl, 3 Methyl 3-buten-1-yl, 1-cyclopenten-1-ylmethyl, (2-methyl-1-cyclopenten-1-yl) methyl, 1-cyclohexen-1-ylmethyl, 2-propyne-1 -yl, 2-butyn-1-yl, 3-butyn-1-yl, 2-chlorobenzyl, 2-bromobenzyl, 2-iodobenzyl-2-cyanobenzyl, 3-fluorobenzyl, 2-methoxybenzyl, 2 -Furanylmethyl, 3-Furanylmethyl-, 2-Thienylmethyl- or 3-Thienylmethylgruppe into consideration.

For example, R ⁴ has the meaning of a (2-aminocyclopropyl) amino, N- (2-aminocyclopropyl) -N-methylamino, (2-aminocyclobutyl) amino, N- (2-aminocyclobutyl) -N-methyl amino, N- (3-aminocyclobutyl) -N-methylamino, (2-aminocyclopentyl) amino, N- (2-aminocyclopentyl) -N-methylamino, N- (3-aminocyclopentyl) - N-methylamino, (2-aminocyclohexyl) amino, N- (2-aminocyclohexyl) -N-methylamino, (3-aminocyclohexyl) amino, N- (3-aminocyclohexyl) -N-methylamino , N- (2-aminoethyl) -N-methyl-amino, N- (1-aminoprop-2-yl) -N-methyl-amino, N- (2-aminopropyl) -N-methyl-amino, N- (1-amino-2-methylprop-2-yl) -N-methylamino, N- (2-amino-2-methylpropyl) -N-methylamino, N - [( 1-aminocyclopropyl) methyl] -N-methyl-amino or N- (1-aminomethylcyclopropyl) -N-methyl-amino group into consideration.

Preference is given to those compounds of the general formula I in which
R ¹ and R ⁴ are defined as mentioned above,
R ^{2 is} a hydrogen atom, a C _1-4 alkyl, C _3-6 cycloalkyl or phenyl group and
R ^{3 is} a 1-buten-1-yl, 2-buten-1-yl, 2-butyn-1-yl, cyclopent-1-enyl-methyl, furanylmethyl, thienylmethyl, chlorobenzyl, bromobenzyl Iodobenzyl, methoxybenzyl or cyanobenzyl group,
their enantiomers, their diastereomers, their mixtures and their salts.

Particular preference is given to those compounds of the general formula I in which
R ^{1 is} a phenylmethyl, phenylcarbonylmethyl, phenylprop-2-enyl, pyridinylmethyl, pyrimidinylmethyl, naphthylmethyl, quinolinylmethyl, isoquinolinylmethyl, quinazolinylmethyl, quinoxalinylmethyl, phenanthridinylmethyl, naphthyridinylmethyl or benzotriazolylmethyl group, each represented by an or two fluoro, chloro, bromo or one or two cyano, nitro, amino, C _1-3 alkyl, C _1-3 alkyloxy and Morpholinylgruppen may be substituted, wherein the substituents are the same or different,
R ^{2 is} a hydrogen atom,
R ^{3 is} a 1-buten-1-yl, 2-buten-1-yl, 2-butyn-1-yl, cyclopent-1-enyl-methyl, furanylmethyl, thienylmethyl, chlorobenzyl, bromobenzyl , Iodobenzyl or cyanobenzyl group and
R ^{4 is} a C _4-6 cycloalkylamino or N- (C _4-6 cycloalkyl) -N- (C _1-3 alkyl) amino group in which the cycloalkyl radical is in either the 2- or 3-position with an amino - or C _1-3 alkylamino group is substituted or in which in the cycloalkyl radical from position 3, a methylene group is replaced by an -NH group, or
an N- (2-aminoethyl) -N-methylamino group in which the ethyl group may be substituted by 1 to 4 methyl groups,
their tautomers, their mixtures and their salts.

Very particular preference is given to those compounds of the general formula I in which
R ^{1 is} an isoquinolinylmethyl, quinazolinylmethyl or benzyl group which may be substituted by a methyl or cyano group,
R ^{2 is} a hydrogen atom,
R ^{3 is} a 2-butyn-1-yl group and
R ^{3 represents} an N- (2-aminoethyl) -N-methylamino, N- (2-aminopropyl) -N-methylamino or N- (2-amino-2-methylpropyl) -N-methylamino group mean,
their tautomers and their salts.

• (a) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (b) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (c) (S)-2-[N-(2-Aminopropyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(2-cyanphenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (d) 2-[N-(2-Amino-2-methylpropyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(2-cyanphenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on

sowie deren Tautomere und deren Salze.For example, the following preferred compounds are mentioned:

• (a) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(4-methylquinazolin-2-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (b) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (c) (S) -2- [N- (2-aminopropyl) -N-methylamino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydro imidazo [4,5-d] pyridazin-4-one
• (d) 2- [N- (2-Amino-2-methylpropyl) -N-methylamino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydro imidazo [4,5-d] pyridazin-4-one

and their tautomers and their salts.

• a) Umsetzung einer Verbindung der allgemeinen Formel
  
  in der R¹ bis R³ wie eingangs erwähnt definiert sind und Z¹ eine Austrittsgruppe wie ein Halogenatom, eine substituierte Hydroxy-, Mercapto-, Sulfinyl-, Sulfonyl- oder Sulfonyloxygruppe wie ein Chlor- oder Bromatom, eine Methansulfonyl- oder Methansulfonyloxygruppe darstellt, mit R⁴-H oder Salzen davon, wobei R⁴ wie eingangs definiert ist.

According to the invention, the compounds of general formula I are obtained by processes known per se, for example by the following processes:

• a) reaction of a compound of the general formula
  
  in which R ¹ to R ³ are defined as mentioned above and Z ^{1 represents} a leaving group such as a halogen atom, a substituted hydroxy, mercapto, sulfinyl, sulfonyl or sulfonyloxy group such as a chlorine or bromine atom, a methanesulfonyl or methanesulfonyloxy group, with R ⁴ -H or salts thereof, wherein R ^{4 is} as defined above.

• b) Entschützung einer Verbindung der allgemeinen Formel
  
  in der R¹, R² und R³ wie eingangs erwähnt definiert sind und Z² eine der eingangs für R⁴ erwähnten Gruppen darstellt, die eine nicht direkt an das Imidazopyridazinon-Grundgerüst gebundene Aminogruppe enthalten, welche in Z² Boc-geschützt ist, wobei Boc für einen tert.-Butyloxycarbonylrest steht.

The reaction is conveniently carried out in a solvent such as isopropanol, butanol, tetrahydrofuran, dioxane, dimethylformamide, dimethyl sulfoxide, ethylene glycol monomethyl ether, ethylene glycol diethyl ether or sulfolane optionally in the presence of an inorganic or tertiary organic base, for example sodium carbonate, potassium carbonate or potassium hydroxide, a tertiary organic base, for example triethylamine, or in the presence of N-ethyl-diisopropylamine (Hünig's base), these organic bases also being able to serve as solvent at the same time, and optionally in the presence of a reaction accelerator such as an alkali halide or a palladium-based catalyst at temperatures between -20 and 180 ° C, but preferably at temperatures between -10 and 120 ° C performed. However, the reaction can be carried out without solvent in an excess of ethylenediamine derivative under conventional heating or in a microwave oven.

• b) Deprotection of a compound of the general formula
  
  in which R ¹ , R ² and R ³ are defined as mentioned above and Z ^{2 is} one of the groups mentioned in the introduction for R ⁴ which contain an amino group which is not bonded directly to the imidazopyridazinone skeleton and which is Boc-protected in Z ² , wherein Boc is a tert-Butyloxycarbonylrest.

The Cleavage of the tert-Butyloxycarbonylrestes is preferably carried out by treatment with an acid such as trifluoroacetic acid or hydrochloric acid or by treatment with bromotrimethylsilane or iodotrimethylsilane optionally using a solvent such as methylene chloride, Essigester, dioxane, methanol, isopropanol or diethyl ether at Temperatures between 0 and 80 ° C.

at The reactions described above may optionally be present reactive groups such as amino, alkylamino or imino groups during the Implementation by usual Protected by protective groups will be split off after the implementation.

For example come as protective remnants for an amino, alkylamino or imino group the formyl, acetyl, Trifluoroacetyl, ethoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, Benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and for the amino group additionally the phthalyl group into consideration.

The optionally subsequent Cleavage of a protective moiety used is carried out, for example, hydrolytically in an aqueous Solvent, e.g. in water, isopropanol / water, acetic acid / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali metal base such as sodium hydroxide or potassium hydroxide or aprotic, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 120 ° C, preferably at temperatures between 10 and 100 ° C.

The Cleavage of a benzyl, methoxybenzyl or Benzyloxycarbonylrestes however, for example, is carried out by hydrogenolysis, e.g. with hydrogen in the presence of a catalyst such as palladium / carbon in a suitable solvent such as methanol, ethanol, ethyl acetate or glacial acetic acid optionally with the addition of an acid such as hydrochloric acid at temperatures between 0 and 100 ° C, but preferably at room temperatures between 20 and 60 ° C, and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar. The cleavage of a 2,4-dimethoxybenzyl radical takes place however, preferably in trifluoroacetic acid in the presence of anisole.

The Cleavage of a tert-butyl or tert-Butyloxycarbonylrestes is preferably carried out by treatment with an acid such as trifluoroacetic or hydrochloric acid or optionally by treatment with iodotrimethylsilane Use of a solvent such as methylene chloride, dioxane, methanol or diethyl ether.

The Cleavage of a Trifluoracetylrestes is preferably carried out by Treatment with an acid like hydrochloric acid optionally in the presence of a solvent such as acetic acid Temperatures between 50 and 120 ° C or by treatment with caustic soda optionally in the presence of a solvent such as tetrahydrofuran at temperatures between 0 and 50 ° C.

The Cleavage of a phthalyl radical is preferably carried out in the presence of hydrazine or a primary Amines such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane Temperatures between 20 and 50 ° C.

Furthermore, as already mentioned, the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers. Thus, for example, cis / trans mixtures in their cis and trans isomers, and compounds having at least one optically active Carbon atom are separated into their enantiomers.

So For example, the resulting cis / trans mixtures can be allowed to pass through Chromatography into their cis and trans isomers, the obtained Compounds of general formula I, which occur in racemates after methods known per se (see Allinger N.L. and Eliel E.L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of the general Formula I with at least 2 asymmetric carbon atoms due their physicochemical differences according to known Methods, e.g. by chromatography and / or fractional crystallisation, into their diastereomers, which, if they are in racemic Form incurred, then as mentioned above can be separated into the enantiomers.

The Enantiomer separation is preferably carried out by column separation on chiral phases or by recrystallization from an optical active solvents or by reacting with one, with the racemic compound salts or derivatives such as e.g. Ester or amide-forming optically active Substance, especially acids and their activated derivatives or alcohols, and separating the this diastereomeric salt mixture or derivative obtained, e.g. due to different solubilities, where from the pure diastereomeric salts or derivatives of the free antipodes can be released by the action of appropriate means. Especially common, optically active acids are e.g. the D and L forms of tartaric acid or dibenzoyltartaric acid, di-O-p-toluoyl-tartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid or China acid. As an optically active alcohol, for example, (+) - or (-) - menthol and as an optically active acyl radical in amides, for example (+) - or (-) - menthyloxycarbonyl into consideration.

Of Further can the compounds of the formula I obtained in their salts, in particular for the pharmaceutical Use in their physiologically acceptable salts with inorganic or organic acids. As acids come for this for example, hydrochloric acid, Hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic into consideration.

In addition, let the new compounds of the formula I thus obtained, if these contain a carboxy group, if desired subsequently in their salts with inorganic or organic bases, in particular for the pharmaceutical application in their physiologically acceptable Salts, convert. As bases For example, sodium hydroxide, potassium hydroxide, cyclohexylamine, Ethanolamine, diethanolamine and triethanolamine into consideration.

The used as starting materials compounds of the general formulas II and III are either known from the literature or you get this according to methods known from the literature (see Examples I to VII).

As already mentioned at the beginning, have the compounds of the invention the general formula I and their physiologically acceptable Salts have valuable pharmacological properties, in particular an inhibitory effect on the enzyme DPP-IV.

The biological properties of the new compounds were tested as follows:
The ability of the substances and their corresponding salts to inhibit DPP-IV activity can be demonstrated in an experimental setup using an extract of the human colon carcinoma cell line Caco-2 as a DPP-IV source. Differentiation of cells to induce DPP-IV expression was performed as described by Reiher et al. in an article entitled "Increased expression of intestinal cell line Caco-2", published in Proc. Natl. Acad. Sci. Vol. 90, pages 5757-5761 (1993). The cell extract was purified from cells solubilized in a buffer (10mM Tris HCl, 0.15M NaCl, 0.04% aprotinin, 0.5% Nonidet-P40, pH 8.0) by centrifugation at 35,000g for 30 minutes at 4 ° C (to remove cell debris). won.

The DPP-IV assay was performed as follows:
50 μl substrate solution (AFC, amido-4-trifluoromethylcoumarin AFC), final concentration 100 μM, were placed in black microtiter plates. 20 μl assay buffer (final concentrations 50 mM Tris HCl pH 7.8, 50 mM NaCl, 1% DMSO) was pipetted. The reaction was started by adding 30 μl solubilized Caco-2 protein (final concentration 0.14 μg protein per well). The test substances to be tested were typically added prediluted in 20 μl, with the assay buffer volume correspondingly reduced. The reaction was carried out at room temperature, the incubation time was 60 minutes. Thereafter, the fluorescence was measured in a Victor 1420 Multilabel Counter, with the excitation wavelength at 405 nm and the emission wavelength at 535 nm. Blank values (corresponding to 0% activity) were obtained in batches without Caco-2 protein (volume replaced by assay buffer), control values (corresponding to 100% activity) were obtained in batches without added substance. The potency of the respective test substances, expressed as IC ₅₀ values, were calculated from dose-response curves consisting of 11 measurement points each. The following results were obtained:

The produced according to the invention Compounds are well tolerated, for example, after oral administration of 10 mg / kg of the compound of Example 1 to rats no changes in the behavior of the animals could be observed.

In view of the ability to inhibit DPP-IV activity, the compounds of general formula I and their corresponding pharmaceutically acceptable salts of the invention are capable of affecting all those conditions or diseases which may be affected by inhibition of DPP-IV activity NEN. It is therefore expected that the compounds of the invention will be useful in the prevention or treatment of diseases or conditions such as Type 1 and Type 2 diabetes mellitus, diabetic complications (such as retinopathy, nephropathy or neuropathies), metabolic acidosis or ketosis, reactive hypoglycemia, insulin resistance, metabolic Syndrome, dyslipidemias of various genesis, arthritis, atherosclerosis and related diseases, obesity, allograft transplantation, and calcitonin-induced osteoporosis. In addition, these substances are suitable for preventing B cell degeneration such as apoptosis or necrosis of pancreatic B cells. The substances are further suited to improve or restore the functionality of pancreatic cells, in addition to increase the number and size of pancreatic B cells. In addition, and due to the role of glucagon-like peptides, such as GLP-1 and GLP-2 and their linkage with DPP-IV inhibition, it is expected that the compounds of the present invention will be useful, inter alia, to achieve a sedative or anxiolytic effect in addition to favorably influence catabolic states after surgery or hormonal stress responses or to reduce the mortality and morbidity after myocardial infarction. In addition, they are suitable for treating all conditions related to the above-mentioned effects mediated by GLP-1 or GLP-2. The compounds of the invention are also useful as diuretics or antihypertensives and are suitable for the prevention and treatment of acute renal failure. Furthermore, the erfidungsgemäßen compounds for the treatment of inflammatory diseases of the respiratory tract can be used. Likewise, they are suitable for the prevention and treatment of chronic inflammatory bowel diseases such as irritable bowel syndrome (IBS), Crohn's disease or ulcerative colitis as well as in pancreatitis. Furthermore, it is expected that they can be used in any kind of injury or impairment in the gastrointestinal tract as well as, for example, in colitis and enterids. In addition, it is expected that DPP-IV inhibitors, and thus also the compounds of the invention, can be used to treat infertility or to improve human or mammalian fertility, particularly if infertility is associated with insulin resistance or with the polycystic Ovarian syndrome is. On the other hand, these substances are suitable for influencing sperm motility and thus can be used as contraceptives for use in men. Furthermore, the substances are suitable for influencing deficiencies of growth hormone associated with short stature, as well as being useful in all indications where growth hormone can be used. The compounds of the invention are due to their inhibitory effect against DPP IV also suitable for the treatment of various autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, thyroiditis and Basedow's disease etc. In addition, they can be used in viral diseases as well as eg in HIV infections for the stimulation of blood formation, for benign prostate hyperplasia, for gingivitis and for the treatment of neuronal defects and neurodegenerative diseases such as Alzheimer's disease. Described compounds are also to be used for the therapy of tumors, in particular for the modification of tumor invasion as well as metastatization, examples being the use in T-cell lymphomas, acute lymphoblastic leukemia, cell-based thyroid carcinomas, basal cell carcinomas or breast carcinomas. Other indications include stroke, ischemia of various origins, Parkinson's disease and migraine. In addition, other indications are increased follicular and epidermal hyperkeratosis Keratinocyte proliferation, psoriasis, encephalomyelitis, glomerulonephritides, lipodystrophies and psychosomatic, depressive and neuropsychiatric disorders of various origins.

The compounds according to the invention can also be used in combination with other active substances. Therapeutics suitable for such a combination include, for example, antidiabetic agents such as metformin, sulfonylureas (eg, glibenclamide, tolbutamide, glimepiride), nateglinides, repaglinide, thiazolidinediones (eg, rosiglitazone, pioglitazone), PPAR-gamma agonists (eg, GI 262570), and Antagonists, PPAR-gamma / alpha modulators (eg KRP 297), alpha-glucosidase inhibitors (eg acarbose, voglibose), other DPPIV inhibitors, alpha2-antagonists, insulin and insulin analogues, GLP-1 and GLP-1 analogues (eg exendin-4) or amylin. In addition, SGLT2 inhibitors such as T-1095 or KGT-1251 (869682), inhibitors of protein tyrosine phosphatase 1, substances which influence a deregulated production of glucose in the liver, such as, for example, inhibitors of glucose-6-phosphatase, or fructose-1,6- bisphosphatase, glycogen phosphorylase, glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase, glycogen synthase kinase or pyruvate dehydrokinase, lipid lowering agents such as HMG-CoA reductase inhibitors (eg simvastatin, atorvastatin), fibrates (eg bezafibrate, fenofibrate), nicotinic acid and its derivatives, PPAR-alpha agonists, PPAR-delta agonists, ACAT inhibitors (eg Avasimibe) or cholesterol resorption inhibitors such as ezetimibe, bile acid-binding substances such as colestyramine, inhibitors of ileal bile acid transport, HDL-increasing compounds such as inhibitors of CETP or regulators of ABC1 or agents for treatment of obesity, such as sibutramine or r tetrahydrolipostatin, dexfenfluramine, axokine, antagonists of the Cannbinoid1 receptor, MCH-1 receptor antagonists, MC4 receptor agonists, NPY5 or NPY2 antagonists or β ₃ agonists such as SB-418790 or AD-9677 as well as agonists of the 5HT2c receptor.

Besides is a combination with drugs to influence high blood pressure such as. All antagonists or ACE inhibitors, diuretics, β-blockers, Ca antagonists and others or combinations thereof.

The To achieve a corresponding effect required dosage is expediently at intravenous Administration 1 to 100 mg, preferably 1 to 30 mg, and when given orally 1 to 1000 mg, preferably 1 to 100 mg, 1 to 4 times daily. For this can be prepared according to the invention Compounds of formula I, optionally in combination with others Active substances, together with one or more inert usual excipients and / or diluents, e.g. with cornstarch, Lactose, cane sugar, microcrystalline cellulose, magnesium stearate, Polyvinylpyrrolidone, citric acid, Tartaric acid, water, Water / ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, Propylene glycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or their suitable mixtures, in usual galenic preparations such as tablets, dragees, capsules, powders, Suspensions or suppositories incorporated.

The The following examples are intended to explain the invention in more detail:

Preparation of the starting compounds:

Example I

2-bromo-1- (2-butyn-1-yl) -1H-imidazole-4,5-dicarboxylic acid dimethyl ester

A solution of 15.0 g of dimethyl 2-bromo-imidazole-4,5-dicarboxylate, 5.15 ml of 1-bromo-2-butyne and 50 ml of N, N-diisopropylethylamine in 280 ml of tetrahydrofuran is refluxed for one hour , The mixture is evaporated, the residue is mixed with about 100 ml of water and extracted three times with 70 ml of ethyl acetate. The extracts are washed with 50 ml of water, dried and concentrated. The crude product thus obtained is purified by column chromatography on silica gel with methylene chloride / ethanol (1: 0 → 49: 1) as eluent.
Yield: 13.50 g (75% of theory)
R _f value: 0.82 (silica gel, methylene chloride / ethanol = 9: 1)
Mass spectrum (ESI ⁺ ): m / z = 315/317 (Br) [M + H] ⁺

Example II

2-bromo-3- (2-butyn-1-yl) -5-formyl-3H-imidazole-4-carboxylic acid methylester

To a solution of 13.5 g of 2-bromo-1- (2-butyn-1-yl) -1H-imidazole-4,5-dicarboxylic acid dimethyl ester in 220 ml of tetrahydrofuran under argon atmosphere at -70 ° C 43 ml of a 1 M solution of diisobutylaluminum hydride in tetrahydrofuran was added dropwise within 20 minutes. It is stirred for a further four hours at -70 ° C, then 20 ml of a mixture of 1 M hydrochloric acid and tetrahydrofuran are added dropwise. After warming to room temperature, about 200 ml of water are added and extracted three times with 70 ml of ethyl acetate. The combined extracts are dried and concentrated. The crude product thus obtained is purified by column chromatography over silica gel with petroleum ether / ethyl acetate (4: 1 → 1: 1) as the eluent.
Yield: 6.40 g (52% of theory)
Mass spectrum (ESI ⁺ ): m / z = 285/287 (Br) [M + H] ⁺

Example III

2-bromo-3- (2-butyn-1-yl) -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one

To a solution of 1.80 g of methyl 2-bromo-3- (2-butyn-1-yl) -5-formyl-3H-imidazole-4-carboxylate in 25 ml of ethanol at room temperature is added 0.31 ml of hydrazine hydrate, dissolved in 1 ml of ethanol, added dropwise. Five minutes later, 1.5 ml of concentrated acetic acid are added and the mixture is refluxed for 30 minutes. After cooling, the precipitated solid is filtered off with suction, washed with 10 ml of ethanol and 20 ml of diethyl ether and dried.
Yield: 1.25 g (74% of theory)
Mass spectrum (ESI ⁺ ): m / z = 267/269 (Br) [M + H] ⁺

Example IV

2-bromo-3- (2-butyn-1-yl) -5 - [(4-methyl-quinazolin-2-yl) methyl] -3, 5-dihydro-imidazo [4,5-d] pyridazin-4-one

A mixture of 365 mg of 2-bromo-3- (2-butyn-1-yl) -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one, 265 mg of 2-chloromethyl-4-methyl -quinazoline and 210 mg of potassium carbonate in 6 ml of acetonitrile is stirred for 17 h at room temperature. Thereafter, the reaction mixture is filtered through 5 g of alumina with ethyl acetate and the filtrate is concentrated. The residue is triturated in diisopropyl ether, separated from the ether and dried.
Yield: 300 mg (53% of theory)
Mass spectrum (ESI ⁺ ): m / z = 423/425 (Br) [M + H] ⁺

• (1) 2-Brom-3-(2-butin-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on Massenspektrum (ESI⁺): m/z = 422/424 (Br) [M+H]⁺
• (2) 2-Brom-3-(2-butin-1-yl)-5-(2-cyanphenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on Massenspektrum (ESI⁺): m/z = 382/384 (Br) [M+H]⁺

Analogously to Example IV, the following compounds are obtained:

• (1) 2-Bromo-3- (2-butyn-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] -3,5-dihydroimidazo [4,5-d] pyridazin-4-one mass spectrum (ESI ⁺ ): m / z = 422/424 (Br) [M + H] ⁺
• (2) 2-Bromo-3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydroimidazo [4,5-d] pyridazin-4-one mass spectrum (ESI ⁺ ): m / z = 382/384 (Br) [M + H] ⁺

Example V

(S) -2 - [(2-aminopropyl) amino] -3- (2-butyn-1-yl) -5- (2-cyanphenylmethyl) -3,5-dihydro-imidazo [4,5-d] pyridazine -4-one

A mixture of 0.36 g of 2-bromo-3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one , 0.42 g of (S) -1,2-diaminopropane dihydrochloride and 0.52 g of potassium carbonate in 6 ml of N-methylpyrrolidone is stirred at 120 ° C for 2.5 h. Then saturated aqueous sodium chloride solution is added and the precipitate separated. The aqueous phase is extracted with ethyl acetate, the combined organic phases are dried over sodium sulfate and concentrated.
Yield: 580 mg (about 60% pure)
R _f value: 0.30 (silica gel, methylene chloride / methanol / ammonium hydroxide = 90: 10: 0.1)

• (1) 2-[(2-Amino-2-methyl-propyl)amino]-3-(2-butin-1-yl)-5-(2-cyanphenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on R_f-Wert: 0,25 (Kieselgel, Methylenchlorid/Methanol/Ammoniumhydroxid = 90:10:0,1)

Analogously to Example V, the following compound is obtained:

• (1) 2 - [(2-Amino-2-methyl-propyl) -amino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydro-imidazo [4, 5-d] pyridazin-4-one R _f value: 0.25 (silica gel, methylene chloride / methanol / ammonium hydroxide = 90: 10: 0.1)

Example VI

(S) -2 - [(2-tert-butyloxycarbonylamino-propyl) amino] -3- (2-butyn-1-yl) -5- (2-cyanphenylmethyl) -3,5-dihydro-imidazo [4,5- d] pyridazin-4-one

To a solution of 1.04 g of (S) -2 - [(2-aminopropyl) amino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydroimidazole [4,5-d] pyridazin-4-one and 0.54 ml of triethylamine in 200 ml of dichloromethane are added at room temperature to 0.73 g of pyrocarbonic acid di-tert-butyl ester. The solution is stirred for 16 h at room temperature and then concentrated. The residue is taken up in ethyl acetate and washed once each with water, dilute citric acid, water and saturated aqueous sodium chloride solution. Thereafter, the organic phase is dried over sodium sulfate and concentrated. The residue is purified by chromatography on silica gel (petroleum ether / ethyl acetate 1: 1).
Yield: 0.40 g (30% of theory)
Mass Spectrum (ESI ⁺ ): m / z = 476 [M + H] ⁺

• (1) 2-[(2-tert-Butyloxycarbonylamino-2-methyl-propyl)amino]-3-(2-butin-1-yl)-5-(2-cyanphenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on Massenspektrum (ESI⁺): m/z = 490 [M+H]⁺

Analogously to Example VI, the following compound is obtained:

• (1) 2 - [(2-tert-Butyloxycarbonylamino-2-methyl-propyl) -amino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydro-imidazo [ 4,5-d] pyridazin-4-one mass spectrum (ESI ⁺ ): m / z = 490 [M + H] ⁺

Example VII

(S) -2- [N- (2-tert-butyloxycarbonylamino-propyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- (2-cyanphenylmethyl) -3,5 dihydro-imidazo [4,5-d] pyridazin-4-one

To an ice-cooled solution of 0.39 g of (S) -2 - [(2-tert-butyloxycarbonylamino-propyl) amino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3, 5-Dihydro-imidazo [4,5-d] pyridazin-4-one in 5 ml of dimethylsulfoxide is added 0.96 g of potassium tert-butoxide. The mixture is stirred at room temperature until the solution is clear. Then 53 .mu.l of methyl iodide are added, and the solution is stirred for a further 3.5 hours at room temperature. Thereafter, water is added to the reaction solution, the precipitate separated and washed with water. The dried precipitate is purified by chromatography on silica gel (petroleum ether / ethyl acetate 1: 1).
Yield: 0.26 g (66% of theory)
Mass spectrum (ESI ⁺ ): m / z = 490 [M + H] ⁺

• (1) 2-[N-(2-tert-Butyloxycarbonylamino-2-methyl-propyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(2-cyanphenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on Massenspektrum (ESI⁺): m/z = 504 [M+H]⁺

The following compound is obtained analogously to Example VII:

• (1) 2- [N- (2-tert-Butyloxycarbonylamino-2-methyl-propyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3 , 5-dihydro-imidazo [4,5-d] pyridazin-4-one mass spectrum (ESI ⁺ ): m / z = 504 [M + H] ⁺

Preparation of the end compounds:

example 1

2- [N- (2-aminoethyl-N-methyl-amino] -3- (2-butyn-1-yl) -5 - [(4-methyl-quinazolin-2-yl) methyl] -3,5- dihydro-imidazo [4,5-d] pyridazin-4-one

A mixture of 300 mg of 2-bromo-3- (2-butyn-1-yl) -5 - [(4-methylquinazolin-2-yl) methyl] -3,5-dihydro-imi dazo [4,5-d] pyridazin-4-one, 400 mg of N-methyl-ethylenediamine and 210 mg of potassium carbonate in 6 ml of dimethyl sulfoxide is stirred at 60 ° C for 8 h. Then, saturated aqueous sodium chloride solution is added, and the aqueous phase is extracted with ethyl acetate. The combined organic phases are dried over sodium sulfate and concentrated. The crude product is purified by chromatography on a silica gel column with methylene chloride / methanol (3: 2) as the eluent.
Yield: 85 mg (29% of theory)
Mass spectrum (ESI ⁺ ): m / z = 417 [M + H] ⁺

Massenspektrum (ESI⁺): m/z = 416 [M+H]⁺ The following compound is obtained analogously to Example 1: (1) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(3-methylisoquinoline -1-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one

Mass Spectrum (ESI ⁺ ): m / z = 416 [M + H] ⁺

Example 2

(S) -2- [N- (2-Amino-propyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- (2-cyanphenylmethyl) -3,5-dihydro- imidazo [4,5-d] pyridazin-4-one

To a solution of 250 mg of (S) -2- [N- (2-tert-butyloxycarbonylamino-propyl) -N-methylamino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl ) -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one in 5 ml of dichloromethane is added dropwise 1.4 ml of trifluoroacetic acid. The solution is stirred for 4 h at room temperature, then diluted with dichloromethane and made alkaline with saturated aqueous sodium carbonate solution. The organic phase is separated, washed with water, dried over magnesium sulfate and concentrated. The residue is stirred with tert-butyl methyl ether and dried after removal of the ether at 40-50 ° C in a vacuum.
Yield: 161 mg (81% of theory)
Mass spectrum (ESI ⁺ ): m / z = 390 [M + H] ⁺

Massenspektrum (ESI⁺): m/z = 404 [M+H]⁺ The following compound is obtained analogously to Example 2: (1) 2- [N- (2-amino-2-methyl-propyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- ( 2-cyano-phenylmethyl) -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one

Mass spectrum (ESI ⁺ ): m / z = 404 [M + H] ⁺

• (1) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-cyan-naphth-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (2) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(2-cyan-phenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (3) 2-[(2-Aminocyclohex-1-yl)amino]-3-(2-butin-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (4) 2-[N-(2-Aminocyclopropyl)amino]-3-(2-butin-1-yl)-5-(2-cyan-phenylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (5) 2-[N-(Pyrrolidin-3-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-cyan-chinolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (6) 2-[N-(2-Aminoprop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-((4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (7) 2-[N-(2-Amino-2-methyl-prop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(phenylcarbonylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (8) 2-[N-(2-Amino-prop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[3-(2-nitrophenyl)prop-2-en-1-yl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (9) 2-[N-(1-Aminocycloprop-1-ylmethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (10) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(3-chlor-2-cyan-phenyl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (11) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-([1,5]naphthyridin-2-ylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (12) 2-[N-(2-Aminoprop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(chinoxalin-6-ylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (13) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(chinazolin-7-ylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (14) 2-[N-(2-Aminoprop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(1-cyan-isochinolin-3-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (15) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-morpholin-4-ylchinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (16) 2-[N-(2-Aminoprop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-phenyl-pyrimidin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (17) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(2,3-dimethyl-chinoxalin-6-ylmethyl)-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (18) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(1-cyan-isochinolin-3-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (19) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(3-methoxy-phenyl)carbonylmethyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (20) 2-[N-(2-Aminoprop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(2-methoxy-phenyl)carbonylmethyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (21) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(2-buten-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (22) 2-[N-(2-Amino-prop-1-yl)-N-methyl-amino]-3-(3-methyl-but-2-en-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (23) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(1-cyclopenten-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (24) 2-[N-(2-Amino-2-methyl-prop-1-yl)-N-methyl-amino]-3-(1-buten-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (25) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-[(2-chlor-phenyl)methyl]-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (26) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-[(2-brom-phenyl)methyl]-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (27) 2-[N-(2-Amino-2-methyl-prop-1-yl)-N-methyl-amino]-3-[(2-iod-phenyl)methyl]-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (28) 2-[N-(2-Amino-prop-1-yl)-N-methyl-amino]-3-[(2-cyan-phenyl)methyl]-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (29) 2-[N-(2-Amino-prop-1-yl)-N-methyl-amino]-3-(furan-2-ylmethyl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (30) 2-[N-(2-Aminoethyl)-N-methyl-amino]-3-(thien-3-ylmethyl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (31) 2-[N-(2-Amino-prop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-(phenanthridin-6-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (32) 2-[N-(2-Amino-prop-1-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[3-(pentafluorphenyl)prop-2-en-1-yl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (33) 2-((Azetidin-3-yl)amino]-3-(2-butin-1-yl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (34) 2-(N-(Azetidin-3-yl)-N-methyl-amino]-3-(2-butin-1-yl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (35) 2-[(2-Amino-2-methylcyclohex-1-yl)amino]-3-(2-butin-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (36) 2-[(3-Methyl-azetidin-3-yl)amino]-3-(2-butin-1-yl)-5-[(4-methyl-chinazolin-2-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (37) 2-[(4-Amino-furan-3-yl)amino]-3-(2-butin-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo[4,5-d]pyridazin-4-on
• (38) 2-[(2-Amino-4-oxo-cyclohex-1-yl)amino]-3-(2-butin-1-yl)-5-[(3-methyl-isochinolin-1-yl)methyl]-3,5-dihydro-imidazo(4,5-d]pyridazin-4-on

Analogously to the above examples and other methods known from the literature, the following compounds can also be obtained:

• (1) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(4-cyanaphth-1-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (2) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5- (2-cyanophenylmethyl) -3,5-dihydroimidazole [4,5-d] pyridazin-4-one
• (3) 2 - [(2-aminocyclohex-1-yl) amino] -3- (2-butyn-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] -3.5 dihydro-imidazo [4,5-d] pyridazin-4-one
• (4) 2- [N- (2-aminocyclopropyl) amino] -3- (2-butyn-1-yl) -5- (2-cyano-phenylmethyl) -3,5-dihydro-imidazo [4,5- d] pyridazin-4-one
• (5) 2- [N- (Pyrrolidin-3-yl) -N-methyl-amino] -3- (2-butyn-1-yl) -5 - [(4-cyano-quinolin-2-yl) -methyl ] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (6) 2- [N- (2-Aminoprop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5 - ((4-methylquinazolin-2-yl ) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (7) 2- [N- (2-Amino-2-methyl-prop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5- (phenylcarbonylmethyl) -3 , 5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (8) 2- [N- (2-Amino-prop-1-yl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- [3- (2-nitrophenyl) prop -2-en-1-yl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (9) 2- [N- (1-Aminocycloprop-1-ylmethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(4-methylquinazolin-2-yl ) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (10) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(3-chloro-2-cyanophenyl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (11) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - ([1,5] naphthyridin-2-ylmethyl) -3, 5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (12) 2- [N- (2-Aminoprop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5- (quinoxalin-6-ylmethyl) -3.5 dihydro-imidazo [4,5-d] pyridazin-4-one
• (13) 2- [N- (2-Aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5- (quinazolin-7-ylmethyl) -3,5-dihydroimidazole [4,5-d] pyridazin-4-one
• (14) 2- [N- (2-Aminoprop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(1-cyano-isoquinolin-3-yl ) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (15) 2- [N- (2-Aminoethyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5 - [(4-morpholin-4-yl-quinazolin-2-yl) -methyl ] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (16) 2- [N- (2-Aminoprop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(4-phenyl-pyrimidin-2-yl ) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (17) 2- [N- (2-Aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5- (2,3-dimethyl-quinoxalin-6-ylmethyl) -3 , 5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (18) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(1-cyanoisoquinolin-3-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (19) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(3-methoxyphenyl) carbonylmethyl] -3,5- dihydro-imidazo [4,5-d] pyridazin-4-one
• (20) 2- [N- (2-Aminoprop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(2-methoxyphenyl) carbonylmethyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (21) 2- [N- (2-aminoethyl) -N-methyl-amino] -3- (2-buten-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (22) 2- [N- (2-amino-prop-1-yl) -N-methyl-amino] -3- (3-methyl-but-2-en-1-yl) -5 - [(3-methyl- isoquinolin-1-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (23) 2- [N- (2-aminoethyl) -N-methylamino] -3- (1-cyclopenten-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (24) 2- [N- (2-Amino-2-methyl-prop-1-yl) -N-methyl-amino] -3- (1-buten-1-yl) -5 - [(3-methyl isoquinolin-1-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (25) 2- [N- (2-aminoethyl) -N-methyl-amino] -3 - [(2-chloro-phenyl) -methyl] -5 - [(4-methyl-quinazolin-2-yl) -methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (26) 2- [N- (2-aminoethyl) -N-methyl-amino] -3 - [(2-bromophenyl) methyl] -5 - [(4-methyl-quinazolin-2-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (27) 2- [N- (2-amino-2-methyl-prop-1-yl) -N-methylamino] -3 - [(2-iodo-phenyl) -methyl] -5 - [(4- methyl-quinazolin-2-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (28) 2- [N- (2-Amino-prop-1-yl) -N-methylamino] -3 - [(2-cyanophenyl) methyl] -5 - [(4-methylquinazoline) 2-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (29) 2- [N- (2-Amino-prop-1-yl) -N-methyl-amino] -3- (furan-2-ylmethyl) -5 - [(4-methyl-quinazolin-2-yl ) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (30) 2- [N- (2-aminoethyl) -N-methylamino] -3- (thien-3-ylmethyl) -5 - [(4-methylquinazolin-2-yl) methyl] -3, 5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (31) 2- [N- (2-Amino-prop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5- (phenanthridin-6-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (32) 2- [N- (2-Amino-prop-1-yl) -N-methylamino] -3- (2-butyn-1-yl) -5- [3- (pentafluorophenyl) prop-2 -en-1-yl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (33) 2 - ((Azetidin-3-yl) amino] -3- (2-butyn-1-yl) -5 - [(4-methylquinazolin-2-yl) methyl] -3,5-dihydro imidazo [4,5-d] pyridazin-4-one
• (34) 2- (N- (Azetidin-3-yl) - N -methyl-amino] -3- (2-butyn-1-yl) -5 - [(4-methyl-quinazolin-2-yl) -methyl ] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (35) 2 - [(2-Amino-2-methylcyclohex-1-yl) amino] -3- (2-butyn-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] -3,5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (36) 2 - [(3-Methylazetidin-3-yl) amino] -3- (2-butyn-1-yl) -5 - [(4-methylquinazolin-2-yl) methyl] -3 , 5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (37) 2 - [(4-Amino-furan-3-yl) -amino] -3- (2-butyn-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] -3 , 5-dihydro-imidazo [4,5-d] pyridazin-4-one
• (38) 2 - [(2-Amino-4-oxo-cyclohex-1-yl) -amino] -3- (2-butyn-1-yl) -5 - [(3-methyl-isoquinolin-1-yl) methyl] -3,5-dihydro-imidazo (4,5-d] pyridazin-4-one

Example 3

Dragées with 75 mg active substance 1 Dragéekern contains: active substance 75.0 mg calcium phosphate 93.0 mg corn starch 35.5 mg polyvinylpyrrolidone 10.0 mg hydroxypropyl methylcellulose 15.0 mg magnesium stearate 1.5 mg 230.0 mg

production:

The active substance is mixed with calcium phosphate, corn starch, polyvinylpyrrolidone, hydroxypropylmethylcellulose and half of the stated amount of magnesium stearate. On a tabletting machine compacts are produced with a diameter of about 13 mm, these are ground on a suitable machine through a sieve with a mesh size of 1.5 mm and mixed with the remaining amount of magnesium stearate. This granulate is pressed on a tabletting machine into tablets of the desired shape. Weight of core: 230 mg Stamp: 9 mm, arched

The thus prepared dragee cores are coated with a film consisting essentially of hydroxypropylmethylcellulose. The finished Filmdragées are shined with beeswax.
Dragée weight: 245 mg.

Example 4

Tablets with 100 mg active substance

Composition: 1 tablet contains: active substance 100.0 mg lactose 80.0 mg corn starch 34.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 2.0 mg 220.0 mg

Production process:

Active ingredient, lactose and starch are mixed and uniformly moistened with an aqueous solution of polyvinylpyrrolidone. After sieving the moist mass (2.0 mm mesh size) and drying in a rack oven at 50 ° C is again sieved (1.5 mm mesh) and the lubricant supplied mixed. The ready-to-use mixture is processed into tablets. Tablet weight: 220 mg Diameter: 10 mm, biplan with facet on both sides and one-sided part notch.

Example 5

Tablets with 150 mg active substance

Composition: 1 tablet contains: active substance 150.0 mg Milk sugar powder. 89.0 mg corn starch 40.0 mg Colloidal silicic acid 10.0 mg polyvinylpyrrolidone 10.0 mg magnesium stearate 1.0 mg 300.0 mg

production:

The with milk sugar, corn starch and silica mixed active substance is moistened with a 20% aqueous solution of polyvinylpyrrolidone and beaten through a sieve of 1.5 mm mesh size.

The granules dried at 45 ° C are again rubbed through the same sieve and mixed with the stated amount of magnesium stearate. From the mixture tablets are pressed. Tablet weight: 300 mg Stamp: 10 mm, flat

Example 6

Hard gelatine capsules with 150 mg active substance 1 capsule contains: active substance 150.0 mg Corn starch drink. about 180.0 mg Milk sugar powder. about 87.0 mg magnesium stearate 3.0 mg about 420.0 mg

production:

Of the Active substance is mixed with the excipients, through a sieve of 0.75 mm mesh size and homogeneous in a suitable device mixed.

The final mixture is filled into size 1 hard gelatin capsules. Capsule filling: about 320 mg Capsule shell: Hard gelatin capsule size 1.

Example 7

Suppositories with 150 mg active substance 1 suppository contains: active substance 150.0 mg Polyethylene glycol 1500 550.0 mg Polyethylene glycol 6000 460.0 mg polyoxyethylene 840.0 mg 2000.0 mg

production:

To the melting of the suppository mass becomes the active ingredient therein distributed homogeneously and the melt poured into pre-cooled molds.

Example 8

Suspension with 50 mg active substance 100 ml suspension contain: active substance 1.00 g Carboxymethylcellulose-Na-salt 0.10 g p-hydroxybenzoate 0.05 g p-hydroxybenzoate 0.01 g cane sugar 10.00 g glycerin 5.00 g Sorbitol solution 70% 20.00 g Aroma 0.30 g Water dist. ad 100 ml

production:

Dest. Water is heated to 70 ° C. Herein, p-hydroxybenzoic acid methyl ester and propyl ester and glycerol and carboxymethyl cellulose sodium salt are dissolved with stirring. It is cooled to room temperature and added with stirring, the active ingredient and dispersed homogeneously. After addition and dissolution of the sugar, the sorbitol solution and the aroma, the suspension is evacuated to vent with stirring.
5 ml of suspension contain 50 mg of active ingredient.

Example 9

Ampoules with 10 mg active substance

Composition: active substance 10.0 mg 0.01 n hydrochloric acid sq Aqua bidest ad 2.0 ml

production:

The Active substance is dissolved in the required amount of 0.01 N HCl, with Saline is isotonic, sterilized by filtration and in 2 ml ampoules bottled.

Example 10

Ampoules with 50 mg active substance

Composition: active substance 50.0 mg 0.01 n hydrochloric acid sq Aqua bidest ad 10.0 ml

production:

The Active substance is dissolved in the required amount of 0.01 N HCl, with Saline is isotonic, sterile filtered and in 10 ml ampoules bottled.

Claims (10)

Compounds of the general formula

R ^{1 represents} an arylmethyl or arylethyl group, a heteroarylmethyl or heteroarylethyl group, an arylcarbonylmethyl group, a heteroarylcarbonylmethyl group or an arylprop-2-enyl or heteroarylprop-2-enyl group in which the propenyl chain is replaced by 1 to 4 fluorine atoms or a cyano, C _1-3 alkyloxy-carbonyl or nitro group may be substituted, R ^{2 is} a hydrogen atom, a C _1-6 alkyl group, an aryl or heteroaryl group, _a substituted by a group R _a C _1-6 alkyl group, wherein R _{a is} a C _3-7 cycloalkyl group in which one or two methylene groups are independently of each other represented by an oxygen or sulfur atom, by an -NH- or -N (C _1-3 -alkyl) group or by a carbonyl, sulfinyl or sulfonyl group, or a trifluoromethyl, aryl, heteroaryl, cyano, carboxy, C _1-3 alkoxy-carbonyl, aminocarbonyl, C _1-3 -alkylamino-carbonyl, di- ( C _1-3 alkyl) amino carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbon yl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4- (C _1-3 alkyl) piperazin-1-ylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C _1-3 alkylsulfinyl , C _1-3 -alkylsulfonyl, hydroxy, C _1-3 -alkoxy, C _1-3 -alkylsulfanyl, amino, C _1-3 -alkylamino, di (C _1-3 -alkyl) - amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl or 4- (C _1-3 alkyl) piperazin-1-yl group, a Trifluoromethyl, carboxy, C _1-4 alkoxycarbonyl, aminocarbonyl, C _1-3 alkylamino-carbonyl, di (C _1-3 alkyl) amino carbonyl, pyrrolidine-1 -ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4- (C _1-3 alkyl) piperazin-1-ylcarbonyl, arylcarbonyl, heteroarylcarbonyl, C _1-3 alkylsulfinyl, C _1-3 alkylsulfonyl, C _1-4 alkoxy, C _1-4 alkylsulfanyl, amino, C _1-3 alkylamino or di (C _1-3 alkyl) -amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl or 4- (C _1-3 alkyl) piperazin-1-yl group , a C _3-7 cycloalkylgr in which one or two methylene groups can be replaced independently of one another by an oxygen or sulfur atom, by an -NH- or -N (C _1-3 -alkyl) group, or by a carbonyl, sulfinyl or sulfonyl group or a C _3-6 alkenyl or C _3-6 alkynyl group, R ³ a C _5-7 cycloalkenylmethyl group optionally substituted by a C _1-3 alkyl group, an arylmethyl or heteroarylmethyl group, a straight-chain or branched C _{2 -8} alkenyl group, which is replaced by 1 to 15 fluorine atoms or a cyano, nitro or C _1-3 alkoxy-carbonyl group, or a straight-chain or branched C _3-8 alkynyl group which may be substituted by 1 to 9 fluorine atoms or a cyano, nitro or C _1-3 alkoxy-carbonyl group and R ^{4 is} an amino group substituted by the radicals R ¹⁵ and R ¹⁶ , in which R ^{15 is} a hydrogen atom, a C _1-6 -alkyl, C _3-6 -cycloalkyl, C _3-6 -cycloalkyl-C _{1- 3} -alkyl-, aryl- or aryl-C _1-3 -alkyl group and R ^{16 represents} an R ¹⁷ -C _2-3 -alkyl group, wherein the C _2-3 -alkyl portion is straight-chain and by 1 to 4 C _1-3 -Alkyl groups, which may be the same or different, and wherein the C _1-3 alkyl group may be linked from position 2 with R ¹⁷ , and R ^{17 represents} an amino or C _1-3 alkylamino group, one by the R ¹⁵ and R ¹⁸ substituted amino group in which R ¹⁵ is defined as mentioned above and R ^{18 is} a in position 1 of the cycloalkyl radical by R ¹⁹ substituted C _3-10 -cycloalkyl-C _1-2 alkyl group e represents a C _3-10 cycloalkyl group substituted in the 1- or 2-position by an R ¹⁹ -C _1-2 alkyl group, wherein R ^{19 represents} an amino or C _1-3 alkylamino group, one represented by R ¹⁵ and R ^{20 is} substituted amino group in which R ¹⁵ is defined as mentioned above and R ^{20 is} a C _4-10 -cycloalkyl group in which a methylene group from position 3 of the C _4-10 -cycloalkyl replaced by an -NH- group is, or is an amino group which is substituted by the radicals R ¹⁵ and R ²¹ and in which R ¹⁵ is defined as mentioned above and R ^{21 is} a C 2 substituted in the 2- or 3-position by an amino or C _1-3 -alkylamino group _3-10 -cycloalkyl group, where the above-mentioned radicals R ¹⁸ , R ²⁰ and R ²¹ may be mono- or disubstituted by R _b , where the substituents may be identical or different and R _{b is} a fluorine atom, a C _{1- 3} alkyl, trifluoromethyl, cyano, amino, C _1-3 alkylamino, hydroxy or C _1-3 -Al kyloxy group and in which one or two methylene groups of the cycloalkyl independently of one another by an oxygen or sulfur atom or by an -NH- or -N (C _1-3 alkyl) - group, or by a carbonyl, sulfinyl or Among the aryl groups mentioned in the definition of the abovementioned radicals are phenyl or naphthyl groups which may be mono-, di- or trisubstituted independently of one another by R _h , where the substituents may be identical or different and R _{h is} a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl, C _1-3 alkoxycarbonyl, aminosulfonyl, methylsulfonyl, acetylamino, methylsulfonylamino, C _1-3 alkyl, cyclopropyl, ethenyl, ethynyl, morpholinyl, hydroxy, C _1-3 alkyloxy, difluoromethoxy or trifluoromethoxy, and in which additionally each hydrogen atom to be replaced by a fluorine atom , the heteroaryl groups mentioned in the definition of the abovementioned radicals may be understood to mean a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, phenanthridinyl, quinolinyl or isoquinolinyl group, or a pyrrolyl , Furanyl, thienyl or pyridyl group in which one or two methine groups are replaced by nitrogen atoms, or an indolyl, benzofuranyl, benzothiophenyl, phenanthridinyl, quinolinyl or isoquinolinyl group in which one to three Methine groups are replaced by nitrogen atoms, or a 1,2-dihydro-2-oxo-pyridinyl, 1,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3-oxo-pyridazinyl-, 1,2 , 3,6-Tetrahydro-3,6-dioxo-pyridazinyl, 1,2-dihydro-2-oxo-pyrimidinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1,2,3,4- Tetrahydro-2,4-dioxo-pyrimidinyl, 1,2-dihydro-2-oxo-pyrazinyl, 1,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl, 2,3-dihydro-2 oxo-indolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxo 1H-benzimidazolyl, 2,3-dihydro-2-oxo-benzoxazolyl, 1,2-dihydro-2-oxo-quinolinyl, 1,4-dihydro-4-oxo-quinolinyl, 1,2-dihydro- 1-oxo-isoquinolinyl, 1,4-dihydro-4-oxo-cinnolinyl, 1,2-dihydro-2-oxo-quinazolinyl, 3,4-dihydro-4-oxo-quinazolinyl, 1,2, 3,4-Tetrahydro-2,4-dioxo-quinazolinyl, 1,2-dihydro-2-oxoquinoxalinyl, 1,2,3,4-tetrahydro-2,3-dioxo-quinoxalinyl, 1,2-dihydro 1-oxo-phthalazinyl, 1,2,3,4-tetrahydro-1,4-dioxo-phthalazinyl, chromanyl, coumarinyl, 2,3-dihydro-benzo [1,4] dioxinyl or 3, 4-dihydro-3-oxo-2H-benzo [1,4] oxazinyl group, and the above-mentioned heteroaryl groups may be mono- or disubstituted by R _h , wherein the substituents may be the same or different and R _{h is} as in the definition of the above-mentioned cycloalkyl radicals, both monocyclic and polycyclic ring systems are to be understood, wherein the multiple cycles are fused, spiro-linked or bridged Unless otherwise stated, the abovementioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched, with the carboxy groups mentioned in the definition of the abovementioned radicals being characterized by an in vivo in a carboxy group-displaceable group or may be replaced by a group negatively charged under physiological conditions, and wherein the amino and imino groups mentioned in the definition of the above-mentioned groups may be substituted by an in-vivo leaving group whose tautomers, enantiomers, diastereomers, their mixtures, their prodrugs and their salts. Compounds of general formula I according to claim 1, in which R ¹ and R ^{4 are defined} as mentioned in claim 1, R ^{2 is} a hydrogen atom, a C _1-4 -alkyl, C _3-6 -cycloalkyl or phenyl group and R ³ a 1-buten-1-yl, 2-buten-1-yl, 2-butyn-1-yl, cyclopent-1-enyl-methyl, furanylmethyl, thienylmethyl, chlorobenzyl, bromobenzyl, iodobenzyl -, methoxybenzyl or cyanobenzyl group, their enantiomers, their diastereomers, mixtures thereof and their salts. Compounds of the general formula I according to Claim 2, in which R ^{1 is} a phenylmethyl, phenylcarbonylmethyl, phenylprop-2-enyl, pyridinylmethyl, pyrimidinylmethyl, naphthylmethyl, quinolinylmethyl, isoquinolinylmethyl, China zolinylmethyl, Chinoxalinylmethyl-, Phenanthridinylmethyl -, Naphthyridinylmethyl- or Benzotriazolylmethylgruppe, each by one or two fluorine, chlorine, bromine or one or two cyano, nitro, amino, C _1-3 alkyl, C _1-3 alkyloxy and Morpholinylgruppen where R ^{2 is} a hydrogen atom, R ^{3 is} 1-buten-1-yl, 2-buten-1-yl, 2-butyn-1-yl, cyclopent-1, and the substituents are the same or different -enylmethyl, furanylmethyl, thienylmethyl, chlorobenzyl, bromobenzyl, iodobenzyl or cyanobenzyl; and R ^{4 is} a C _4-6 cycloalkylamino or N- (C _4-6 cycloalkyl) -N- (C _{1 3-} alkyl) amino group in which the cycloalkyl radical is substituted in either the 2 or 3 position with an amino or C _1-3 alkylamino group or in which in the cycloalkyl radical from position 3 a methylene group is replaced by an -NH group, or an N- (2-aminoethyl) -N-methyl-amino group in which the ethyl group may be substituted by 1 to 4 methyl groups, their tautomers, their mixtures and their salts. Compounds of the general formula I according to claim 3, in which R ^{1 is} an isoquinolinylmethyl, quinazolinylmethyl or benzyl group which may be substituted by a methyl or cyano group, R ^{2 is} a hydrogen atom, R ^{3 is} a 2-butin-1-yl group and R ^{3 is} an N- (2-aminoethyl) -N-methylamino, N- (2-aminopropyl) -N-methylamino or N- (2-amino-2-methylpropyl) -N-methyl- amino group, their tautomers and their salts. The following compounds of general formula I according to claim 1: (a) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(4-methylquinazolin-2-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one (b) 2- [N- (2-aminoethyl) -N-methylamino] -3- (2-butyn-1-yl) -5 - [(3-methylisoquinolin-1-yl) methyl] - 3,5-dihydro-imidazo [4,5-d] pyridazin-4-one (C) (S) -2- [N- (2-aminopropyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- (2-cyanphenylmethyl) -3,5-dihydro-imidazo [ 4,5-d] pyridazin-4-one (D) 2- [N- (2-amino-2-methylpropyl) -N-methyl-amino] -3- (2-butyn-1-yl) -5- (2-cyanphenylmethyl) -3,5-dihydro-imidazo [ 4,5-d] pyridazin-4-one such as their tautomers and their salts. Physiologically acceptable salts of the compounds according to claims 1 to 5 with inorganic or organic acids or bases. A medicament containing a compound according to one the claims 1 to 5 or a physiologically acceptable salt according to claim 6 next to optionally one or more inert carriers and / or diluents. Use of a compound according to any one of claims 1 to 6 for the manufacture of a medicament for the treatment of diabetes mellitus type I and type II, arthritis, obesity, allograft transplant tion and calcitonin-induced osteoporosis. Process for the preparation of a medicament according to claim 7, characterized in that non-chemical Way a compound according to any one of claims 1 to 6 in one or more inert carriers and / or diluents is incorporated. Process for the preparation of the compounds of the general formula I according to Claims 1 to 6, characterized in that a) a compound of the general formula

wherein R ¹ to R ^{3 are defined} as mentioned in claim 1 and Z ^{1 represents} a leaving group such as a halogen atom, a substituted hydroxy, mercapto, sulfinyl, sulfonyl or sulfonyloxy group, with R ⁴ -H or salts thereof, wherein R ⁴ is defined as defined in claim 1; or b) a compound of the general formula

in which R ¹ , R ² and R ^{3 are defined} as mentioned in claim 1 and Z ^{2 represents} one of the groups mentioned in claim 1 for R ⁴ which contain an amino group not directly bonded to the imidazopyridazinone skeleton, which in Z ² Boc Protected, wherein Boc is a tert-Butyloxycarbonylrest is deprotected; and / or subsequently, if appropriate, protective groups used during the reaction are split off and / or the compounds of the general formula I thus obtained are resolved into their enantiomers and / or diastereomers and / or the compounds of the formula I obtained in their salts, in particular for the pharmaceutical application be converted into their physiologically acceptable salts with inorganic or organic acids or bases.